Administration of reduced glutathione in FOLFOX4 adjuvant treatment for colorectal cancer: effect on oxaliplatin pharmacokinetics, Pt-DNA adduct formation, and …
P Milla, M Airoldi, G Weber, A Drescher… - Anti-cancer …, 2009 - journals.lww.com
Oxaliplatin is a promising drug for cancer therapy and the oxaliplatin/5-
fluorouracil/leucovorin (FOLFOX) regimen has become the standard adjuvant treatment for
colorectal cancer. However, the oxaliplatin-induced neurotoxicity still represents a clinical
problem leading to a discontinuation of the therapy. Many strategies have been proposed in
order to manage the neurotoxicity, but their effect on antitumoral efficacy is still unclear. In
this study, we investigated the effect of reduced glutathione administration on neurotoxicity …
fluorouracil/leucovorin (FOLFOX) regimen has become the standard adjuvant treatment for
colorectal cancer. However, the oxaliplatin-induced neurotoxicity still represents a clinical
problem leading to a discontinuation of the therapy. Many strategies have been proposed in
order to manage the neurotoxicity, but their effect on antitumoral efficacy is still unclear. In
this study, we investigated the effect of reduced glutathione administration on neurotoxicity …
